$CARM

Carisma Therapeutics Inc.

No enriched coverage for $CARM in the last 7 days.

No SEC Form 4 filings for $CARM in the last 30 days.

Ocugen ( OCGN ) Q2 Revenue Jumps 20%

Ocugen ( NASDAQ:OCGN ) , a biotechnology company developing gene therapies and regenerative medicine solutions for eye diseases, released its results for the second quarter of fiscal 2025 on August 1, 2025. GAAP revenue was $1.373 million, well above the $0.47 million analyst estimate ( GAAP ) , ...